ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.

Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical aortic valve replacement In low-risk patients with AS. The primary outcome measures were the rates of all-cause mortality or disabling stroke.

Key findings at five years show that the primary endpoint in TAVR remained similar to surgery at every time point across the trial. There were no more reinterventions, and no more moderate or greater paravalvular leak in the TAVR arm compared to the surgical arm. The EVOLUT TAVR system showed superior haemodynamics at every time point across the trial.

Interview Questions:

1. What is the reasoning behind the trial?
2. What was the study design and patient population?
3. What were the key findings?
4. What are the take-home messages for practice?
5. What is the potential impact of these findings on future guidelines?
6. What further research is required?

Recorded on-site at ACC in Chicago, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.